# Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

> **NCT07747506** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Verastem, Inc.** · enrollment: 2 (estimated)

## Conditions studied

- Low Grade Ovarian Serous Adenocarcinoma
- Ovarian Cancer

## Interventions

- **DRUG:** avutometinib + defactininb combination

## Key facts

- **NCT ID:** NCT07747506
- **Lead sponsor:** Verastem, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-03
- **Primary completion:** 2027-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 2 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07747506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07747506, "Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07747506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*